

FOUNDATION FOR PROFESSIONAL DEVELOPMENT

A novel lateral flow assay for point-of-care detection of *Neisseria gonorrhoeae*: Implementation experiences

Mandisa Mdingi, MPH

Research Unit, Foundation for Professional Development

Disclosure

| Any circumstances that could give rise to a potential conflict of interest related to the conference or topic under discussion | Name of company, organization or institution | |
|--|--|--|
| Sponsorship | FIND | |
| Payment or other financial remuneration | None | |
| Shareholder rights | None | |
| Other relations | None | |



Need for affordable POC


- Affordable point-of-care (POC) test is essential to reduce the global burden of Neisseria gonorrhoeae infection
- NG POC target product profile (TPP) was developed for intended use in syndromic management settings and screening of high-risk populations
- TPP requirements for non-molecular test for NG POC detection:

| | Minimal requirement | Optimal requirement |
|----------------|---------------------|---------------------|
| Sensitivity | >80% | >90% |
| Specificity | >95% | >98% |
| Time to result | ≤ 30 minutes | ≤ 10 minutes |



Methods (1)

- FIND team conducted training for managerial staff:
 - followed by onsite training for field team
 - FIND provided "procedure quick cards" to be used for different samples collected
- Step-by-step testing demonstration followed by hands-on practice with demo samples
 - Different results scenarios were explored; negative, positive and invalid (to prepare the team for the reallife situation)





Methods (2)

- Study design: Cross-sectional study of diagnostic performance of LFA compared to Xpert® CT/NG Assay as gold standard
- Study location: 5 primary healthcare facilities
 - In-facility GeneXpert® testing
 - IRB approved: reference number 510/2021

Study population:

- Men with MUS (n=200)
- Women with VDS (n=200)
- Asymptomatic men (n=500) and Asymptomatic women (n=500)





Lateral flow assay procedure



Prepare buffer



Prepare specimen



Mix specimen and buffer



Prepare cartridge while waiting



Inoculate cartridge



Do other things while waiting



Use reader for result





RESULT!



Results

Symptomatic evaluation

| | Male patients (n=200) | Female patients (n=200) |
|-------------------------------------|--------------------------|-------------------------|
| Neisseria gonorrhoeae prevalence | 128 (64%) | 36 (18%) |
| Sensitivity | 96.1% (91.2-98.3) | 91.7% (78.2–97.1) |
| Specificity | 97-2% (90-4-99-2) | 96.3% (92.2–98.3) |
| Positive predictive value | 98-4% (94-4-99-6) | 84.6% (70.3–92.8) |
| Negative predictive value | 93·3% (85·3-97·1) | 98.1% (94.7-99.4) |
| Accuracy | 96.5% (93.0-98.3) | 95.5% (91.7-97.7) |

Table 3: Diagnostic performance characteristics of Neisseria gonorrhoeae lateral flow assay compared with Xpert for the detection of N gonorrhoeae in symptomatic male and female patients

Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation

Remco P H Peters, Jeffrey D Klausner, Laura Mazzola, Mandisa M Mdingi, Hyunsul Jung, Ranjana M S Gigi, Jeremie Piton, Joseph Daniels, Lindsey de Vos, Paul C Adamson, Birgitta Gleeson, Cecilia Ferreyra

Asymptomatic evaluation

| | Males (n=500) | Females(n=400) |
|-----------------------|-----------------------|-----------------------|
| Neisseria gonorrhoeae | 6.2% | 8.3% |
| prevalence | | |
| Sensitivity | 80.6% (63.7% - 90.8%) | 81.8% (65.6% - 91.4%) |
| Specificity | 94.2% (91.8% - 96.0%) | 98.1% (96.1% - 99.1%) |

Peters (unpublished, submitted to Lancet Infectious Diseases)



Usability and acceptability

 Results of the usability and acceptability: highly acceptable and usable even among non-professional nurses (field workers)

> de Vos (2023) PloS ONE DOI:10.1371/journal.pone.0286666

RESEARCH ARTICLE

Usability of a novel lateral flow assay for the point-of-care detection of *Neisseria* gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa

Lindsey de Voso¹°, Joseph Daniels²°*, Avuyonke Gebengu¹, Laura Mazzola³, Birgitta Gleeson³, Jérémie Piton³, Mandisa Mdingi¹, Ranjana Gigi¹,⁴, Cecilia Ferreyra³, Jeffrey D. Klausner⁵, Remco P. H. Peterso¹, 1.6.7*

de Vos (2024) BMC Health Service Research DOI: 10.1186/s12913-023-10478-8

RESEARCH

Open Access


Implementation considerations for a pointof-care *Neisseria gonorrhoeae* rapid diagnostic test at primary healthcare level in South Africa: a qualitative study

Lindsey de Vos^{1†}, Joseph Daniels^{2+†}, Avuyonke Gebengu¹, Laura Mazzola³, Birgitta Gleeson³, Benjamin Blümel³, Jérémie Piton³, Mandisa Mdingi¹, Ranjana M.S. Gigi^{1,4}, Cecilia Ferreyra³, Jeffrey D. Klausner⁵ and Remco P.H. Peters^{1,6,}



Potential impact of the assay on clinic flow

- Any staff category can perform the test
 - alleviates pressure from the professional nurses
 - reduce waiting times
- Accommodates space constraints and potential stigma concerns
- Increased awareness of STI types amongst patients
- Investment in health improving technologies





Next steps

- Performance of LFA in symptomatic nonpregnant women using self-collected samples
 - Usability and acceptability
- Performance of LFA in pregnant women





Conclusion

 The novel lateral flow assay provides a promising POC test that may strengthen STI treatment in syndromic management settings



Thank you







